在高危肝细胞癌患者中对小肝结节(≤2 cm)的钆塞酸增强通量分析
本研究回顾性纳入2017年8月1日至2021年12月31日接受钆塞酸增强MRI并手术切除的156例高危患者181个肝结节作为训练集,前瞻性纳入2022年1月1日至2022年10月1日36例患者42个结节作为测试集,采用双指数函数拟合的新型增强通量分析区分良性结节与肝细胞癌,并与既往发表的ERmax、PSR、ERmax+PSR模型比较AUC。新型增强通量分析在训练集和测试集中AUC均最高。
要点
- 新型双指数增强通量分析在训练集AUC为0.897,测试集为0.859,均高于PSR、ERmax及ERmax+PSR模型。
- 训练集中PSR、ERmax、ERmax+PSR的AUC分别为0.801、0.620、0.799。
- 测试集中PSR、ERmax、ERmax+PSR的AUC分别为0.701、0.529、0.708。
核心结论
- 钆塞酸增强MRI的双指数通量分析在准确诊断小肝细胞癌结节方面展现出更好的潜力。
研究设计与样本
- 训练集为回顾性收集的2017年8月1日至2021年12月31日156例高危患者181个肝结节,测试集为前瞻性收集的2022年1月1日至2022年10月1日36例患者42个结节,均接受钆塞酸增强MRI及后续手术切除。
诊断标准与关键数值
- 新型增强通量分析训练集AUC 0.897(95%CI: 0.833-0.960),测试集AUC 0.859(95%CI: 0.747-0.970)。
- PSR训练集AUC 0.801(95%CI: 0.710-0.891),测试集AUC 0.701(95%CI: 0.539-0.863)。
- ERmax训练集AUC 0.620(95%CI: 0.510-0.729),测试集AUC 0.529(95%CI: 0.342-0.717)。
- ERmax+PSR训练集AUC 0.799(95%CI: 0.709-0.889),测试集AUC 0.708(95%CI: 0.549-0.867)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To discriminate between benignities and hepatocellular carcinomas (HCCs) in patients at high risk of HCC using a novel enhancement flux analysis for gadoxetic-acid enhanced MRI.
METHOD: This study retrospectively collected 181 liver nodules in 156 patients at high risk of HCC who underwent gadoxetic acid-enhanced MRI examinations with following surgical resection from 1st August 2017 to 31st December 2021 as the training set; another 42 liver nodules in 36 patients were prospectively collected from 1st January 2022 to 1st October 2022 as the test set. The time-intensity curves (TICs) of liver nodules were formed with consecutive time points: 0 s, 20 s, 1 min, 2 min, 5 min, 10 min, 15 min, and 20 min since contrast injection. A novel enhancement flux analysis was applied by using a biexponential function fitting to distinguish benignities and HCC. Besides, previously published models including maximum enhancement ratio (ERmax), percentage signal ratio (PSR), and ERmax+PSR were compared. The areas under the receiver operating characteristic curves (AUCs) were compared among these methods.
RESULTS: The novel enhancement flux analysis showed the highest AUCs in the training set (0.897, 95%CI: 0.833-0.960) and the test set (0.859, 95%CI: 0.747-0.970) among all models. The AUCs of PSR, ERmax and ERmax+PSR were 0.801 (95%CI: 0.710-0.891), 0.620 (95%CI: 0.510-0.729), and 0.799 (95%CI: 0.709-0.889) in the training set, and were 0.701 (95%CI: 0.539-0.863), 0.529 (95%CI: 0.342-0.717), and 0.708 (95%CI: 0.549-0.867) in the test set.
CONCLUSIONS: The biexponential flux analysis for gadoxetic-acid enhanced MRI presents a better potential in accurate diagnosis of small HCC nodules.
引用
- Chen, Wang, Guo, et al. A gadoxetic-acid enhancement flux analysis of small liver nodules (≤2 cm) in patients at high risk of hepatocellular carcinoma. Eur J Radiol. 2023. PMID: 37300937. doi:10.1016/j.ejrad.2023.110911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。